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Primary immunodeficiencies (PIDs) are rare disorders of the immune system
encompassing inborn errors of immunity. Primary antibody deficiencies constitute
the largest group of PID with common variable immunodeficiency (CVID) being the
most common symptomatic form. Combined immunodeficiencies (CID) accompanied
by antibody deficiency can mimic CVID and these patients need the verification of
the final diagnosis. Respiratory involvement, especially interstitial lung disease (ILD),
poses a relevant cause of morbidity and mortality among patients with PID and in
some cases is the first manifestation of immunodeficiency. In this study we present
a retrospective analysis of a group of children with primary immunodeficiency and
ILD - the clinical, radiological, histological characteristics, treatment strategies and
outcomes. Eleven children with PID-related ILD were described. The majority of
them presented CVID, in three patients CID was recognized. All patients underwent
detailed pulmonary diagnostics. In eight of them histological analysis of lung biopsy
was performed. We noted that in two out of 11 patients acute onset of ILD
with respiratory failure was the first manifestation of the disease and preceded PID
diagnosis. The most common histopathological diagnosis was GLILD. Among the
analyzed patients three did not require any immunosuppressive therapy. All eight treated
children received corticosteroids as initial treatment, but in some of them second-line
therapy was introduced. The relevant side effects in some patients were observed.
The study demonstrated that the response to corticosteroids is usually prompt.
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However, the resolution of pulmonary changes may be incomplete and second-line
treatment may be necessary.
Keywords: computed tomography, children, CVID, interstitial lung disease, primary immunodeficiency, GLILD
INTRODUCTION
Primary immunodeficiencies (PIDs) are inherited disorders of
the immune system encompassing inborn errors of immunity.
The clinical spectrum of PIDs is broad, ranging from relatively
mild disorders selectively affecting immune defense mechanisms
to serious, life-threatening diseases characterized by profound
lack of immune functions. According to a report by the
International Union of Immunological Societies (IUIS), over
400 distinct disorders are recognized (1). Estimates by Bousfiha
et al. suggest that ∼6 million people may be affected worldwide,
though only ∼60,000 cases of PIDs are currently definitively
diagnosed (2). Ten phenotypic categories of PIDs are recognized
according to the underlying immune defects (3). Primary
antibody deficiencies (PADs) are the largest group of PIDs,
accounting for ∼55% of PIDs in Europe (www.esid.com) and
up to 78% in the USA (4). PADs predominantly result from a
primary defect in B cells, but can also be caused by defects in T
cells or other immune cell populations that contribute to B-cell
or plasma cell development and function. Antibody deficiencies
are characterized by a malfunctioning antibody response, which
is reflected in low or undetectable levels of immunoglobulin(s).
Common variable immunodeficiency (CVID), with an
incidence of 1:25,000–1:50,000, is one of the most prevalent
symptomatic PADs (5–7). Some well-defined disorders (e.g.,
combined immunodeficiencies—CID) accompanied by antibody
deficiency can mimic CVID, and only new diagnostic tools,
including next-generation sequencing (NGS), enable the
verification of the final diagnosis (8, 9).
Patients with antibody deficiency present with a broad
spectrum of manifestations. In addition to recurrent infections,
non-infectious complications such as interstitial lung disease
(ILD), gastrointestinal inflammatory disease, hematologic
or organ-specific autoimmunity, lymphoproliferation, and
lymphoma may occur (5–8). Respiratory diseases are a cause of
morbidity and mortality among PID patients, and in some cases
lung disease may play an important role in diagnosis as the first
manifestation of PID (10–14). Lung involvement in patients with
PID can be infection-related, immune-mediated, or associated
with the occurrence of neoplastic diseases. In cases of infection-
related lung disease, effective protection can be provided by
immunoglobulin replacement therapy (IgRT); however, it does
not prevent non-infectious pulmonary involvement (6, 12).
ILDs represent one of the most significant immune-mediated
complications of PID (14). The most common form of PID-
related ILD is granulomatous-lymphocytic ILD (GLILD), an
umbrella term that encompasses a spectrum of lung pathologies:
various forms of pulmonary lymphoid hyperplasia [lymphocytic
interstitial pneumonia (LIP), follicular bronchiolitis (FB),
nodular lymphoid hyperplasia, and granulomatous disease], as
well as organizing pneumonia (10, 14, 15). The risk of death
in CVID patients with non-infectious complications like ILD
has been shown to be several times higher than in patients
with infectious complications only (16). CVID-related GLILD
significantly shortens life expectancy (17).
Previous reports concerning PID-related ILD are mainly
limited to adults; data regarding disease specificity and
exceptionality of pediatric patients available in the literature are
insufficient. Herein we present a retrospective analysis of the
clinical, radiological, and histological characteristics, as well as
treatment strategies and outcomes, in a unique group of children
with PID-related ILD, predominantly CVID patients.
MATERIALS AND METHODS
Retrospective analysis of clinical data from children with
PID-related ILD consulted or treated consecutively in the
Department of Immunology at the Children’s Memorial Health
Institute (CMHI) of Warsaw and the Department of Pediatric
Pneumonology and Allergy at the Medical University of Warsaw
between 2012 and 2019 is presented.
The major inclusion criterion was the diagnosis of PID,
mostly CVID. Diagnosis of CVID was established according to
ESID diagnostic criteria (18). Since CVID encompasses a group
of heterogenous antibody deficiencies with many monogenic
forms, detailed immunophenotyping and genetic studies using
next-generation sequencing (NGS), Sanger sequencing, or
fluorescence in situ hybridization (FISH) were performed in
six individuals to better characterize the study group. In
five patients genetic tests were not performed because of:
technical problems with genetic testing and consent not given
by parents. Following laboratory and/or molecular studies,
combined immunodeficiency (CID) was diagnosed in three
individuals: one with Nijmegen breakage syndrome (NBS), one
with DiGeorge Syndrome (DGS), and one with LRBA.
Diagnosis of PID-related ILD was based on (1) clinical signs
and symptoms [tachypnea [defined as respiratory rate >90th
percentile (19)], retractions, crackles]; (2) typical computed
tomography (CT) findings [multiple nodules of different
densities with perilymphatic or interlobular distribution
predominantly in the middle and lower zones of the lungs and
hilar or mediastinal lymphadenopathy (transverse dimension of
the lymph nodes >1 cm)]; and (3) histopathology of lung biopsy
with findings consistent with GLILD, cryptogenic organizing
pneumonia (COP), LIP, FB, or lymphoid hyperplasia.
Exclusion criteria were other ILDs, coexistence of other
chronic lung diseases (e.g., cystic fibrosis), and acute or chronic
respiratory infections.
Data Collection
Prespecified data on all children with PID and related ILD
were collected. These included (1) demographic data; (2)
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clinical signs and symptoms such as dyspnea, tachypnea, cough,
cyanosis, crackles, wheezing, respiratory failure, finger clubbing,
splenomegaly, hepatomegaly, lymphadenopathy, hemolytic
anemia, thrombocytopenia, and history of chronic lung diseases;
(3) the results of the following laboratory tests: total blood count,
detailed immunological screening (including immunoglobulin
level and immunophenotyping of lymphocytes, with B- and
T-cell functional tests and genetic testing in some cases); (4) the
results of pulmonary function tests, including spirometry, body
plethysmography, and diffusing capacity for carbon monoxide
(DLCO); (5) the results of lung high-resolution computed
tomography (HRCT) and chest magnetic resonance imaging
(MRI); (6) histopathology of lung biopsy; and (7) treatment
regimens [corticosteroids, other immunosuppressive drugs (e.g.,
azathioprine, mycophenolate mofetil, rapamycin, cyclosporin),
IgRT, and hematopoietic stem cell transplantation (HSCT)],
duration, and outcomes.
The immune status of patients was assessed based on
serum immunoglobulin concentration, antibody response to
vaccines and/or isohemagglutinins titer, immunophenotyping
of lymphocytes with switch memory B cells numbers, and
lymphoproliferation tests as described previously [(20–22); data
not shown]. The sources of data were an electronic database of
patients with PID and medical records of patients with PID-
related ILD.
Imaging Studies
In eight children, volumetric CT examinations were performed
with either a 320-row multidetector computed tomography
scanner (Aquilion ONE, Toshiba, Japan; three children) or a 128-
row multidetector computed tomography scanner (SOMATOM
Definition AS, Siemens, Germany; five children) and images
were reconstructed using a high-resolution reconstruction
algorithm. In the remaining two patients, CT scans performed
in local hospitals were used for analysis. Contrast medium was
administered in eight patients. Pulmonary involvement in the
child withNBSwith a known radiosensitivity wasmonitored with
chest MRI.
Pulmonary Function Tests
Spirometry tests were obtained in nine cooperating individuals
and included forced vital capacity (FVC) and forced expiratory
volume in 1 second (FEV1). All pulmonary function tests were
performed in the sitting position using a spirometer (Lungtest
1000 MES, Poland, or JAEGER MasterScreen, Germany)
according to the ERS (European Respiratory Society) guidelines
for lung function testing (23). All spirometric results were
presented as percentiles (pc). FVC, FEV1, and FEV1/FVC ≥5th
pc were considered normal. Obstruction was diagnosed if the
FEV1/FVC ratio was below the 5th pc. DLCO was measured
using the single-breath method using a Vmax22 spirometer
(SensorMedics, USA), or MasterScreen (CareFusion, USA) and
results between the 5th and 95th pc were considered to be
within the normal range. The whole-body plethysmography
was performed using a Lungtest 1000 (MES, Poland), or
MasterScreen (CareFusion, USA). Total lung capacity (TLC) and
residual volume (RV) were calculated for each patient. TLC
lower than the 5th pc was considered to indicate restriction. Air
trapping was defined as a RV/TLC ratio above the 95th pc.
Histological Assessment
Lung biopsies were performed in eight of the 11 patients. The
obtained material was then fixed in 10% buffered formalin
solution and paraffin embedded (FFPE). Microscopic slides
with 4-µm FFPE sections were stained with hematoxylin
and eosin (H + E) and in some cases immunohistochemical
markers were used (CD3, CD20, CD5, CKAE1/AE3, and Ki-
67; Ventana Roche, USA). Immunohistochemical tests were
performed using an automated Ventana Benchmark GX Slide
Staining System according to the manufacturer’s protocol. In two
cases, mediastinal lymph nodes biopsies were analyzed.
Statistical Analysis
The results of the study were summarized using standard
descriptive statistics. Data are presented as median and range.
The studies involving human participants were reviewed
and approved by The Bioethics Committee of the Children’s
Memorial Health Institute inWarsaw (approval no.9/KBE/2020).
All parents or legal guardians, as well as patients older than 16
years of age, gave their written consent to participate in the study.
RESULTS
Demographic and Clinical Data
Eleven children with interstitial lung disease were selected from
the database of 796 children with PID followed-up between
2012 and 2019. Detailed immunological and genetic diagnostics
enabled the diagnosis of CVID in nine patients however, in one of
these patients, finally an NGS panel revealed an LRBA mutation.
The other two patients with a provisional diagnosis of PAD were
eventually diagnosed with CID with associated features (NBS in
the patient with hydrocephaly and DGS in the patient without
an expressive dysmorphia). In three patients with CVID no
mutations were confirmed.
All of the children diagnosed with PID-related ILD were boys.
The median age at the diagnosis of antibody deficiency was
9.5 years (range 4–17 years). Six patients had never developed
respiratory symptoms (except respiratory tract infections).
Chest imaging studies were performed for other reasons
(e.g., generalized lymphadenopathy) and revealed pulmonary
involvement. Five patients were symptomatic in terms of
respiratory involvement. In two children, the symptoms of ILD
preceded the recognition of immunodeficiency, so the median
age at the onset of ILD symptoms was 6.5 years (range 2–16). The
severity of ILD symptoms was diverse, with one child presenting
with a mild cough (patient No. 4; Table 1) and three others with
life-threatening respiratory failure (patients No. 3, 7, and 8).
Detailed demographic data and clinical symptoms are
presented in Table 1.
Computed Tomography
Lung CT was performed in 10 patients. One child with NBS
had been diagnosed and followed with chest MRI to avoid
radiation exposure.


















TABLE 1 | Baseline clinical characteristics at diagnosis.
Patient 1 2 3 4 5 6 7 8 9 10 11
Age, sex 13, M 19, M 13, M 19, M 5, M 16, M 10, M 12, M 11, M 18, M 17, M















































+ – – – – – – – + + +
Age at ILD diagnosis 8 yr 17 yr 11 yr 13 yr 4 yr 16 yr 2.5 yr 10 yr 9 yr 10 yr 14 yr
Age at PID diagnosis 5 yr 17 yr 12 yr 12 yr 4 yr 16 yr 7 yr 4 yr 5 yr 15 yr 14 yr
Immunodeficiency CVID CVID CVID CVID LRBA CVID CVID NBS CVID DGS CVID














Chronic cough + – – + – – – + – – –
Dyspnea – – + – – – + + – – –
Crackles + – + + – – + + – – –
Clubbed fingers – – – – – – + – – – –
Acute respiratory
insufficiency
– – + – – – + + – – –
Extra-pulmonary manifestation:
Hepatomegaly + + + – + + + – + + –
Splenomegaly – + + – + + + – + + _
Lymphadenopathy + + – + + + – – + + +
Cytopenia:
Anemia – + – – + + + – – – –
Leukopenia – + – – + + – – + – –
Thrombocytopenia + – – – + + + – + – –
Lung HRCT findings*:
Nodules + + + + + + + + + + +
Perilymphatic
distribution
+ + + + + + – – – + +
Middle and lower zone
predominance
+ + + + – + – + – + –
Intrathoracic
lymhadenopathy











































































































































































































































































































































































































































































































































































































































Multiple, mostly poorly defined pulmonary nodules were
revealed in all children assessed. The diameter of the nodules
ranged from 2 to 30mm and their density varied from solid
to part-solid to ground glass opacity (Figures 1A, 2, 3). Solid
nodules were surrounded by a ground-glass halo in four patients.
In most of the children, nodules had a perilymphatic distribution
with a predilection for the middle and lower lung zones. The
lesions formed rosettes and a “tree-in-bud” pattern in one
patient (Figure 2). Interlobular septal thickenings or irregular
linear opacities were found in one case each. The changes
described above were accompanied by hilar and/or mediastinal
lymphadenopathy in seven patients (Figure 4).
During the exacerbations of ILD, progression of lung
involvement in imaging studies was observed, with an increase
in the number, size, and density of lung nodules as well as
extensive areas of ground-glass opacities and parenchymal lung
consolidations (Figures 1A,C).
Pulmonary Function Tests
Pulmonary function tests (PFTs) were performed in nine
children. Two children were unable to perform PFT, one due
to the young age and the other due to intellectual disability. All
of the PFTs were performed in the stable phase of the ILD. The
results of PFT are shown inTable 2.We found one patient (No. 3)
with a restrictive ventilatory pattern and five with air trapping
(No. 2, 4, 9, 10, and 11). DLCO was abnormal in two patients.
A mild reduction of DLCO was found in patient No. 2 (74%
of predicted value) and a moderate reduction was observed in
patient No. 3 (50% of predicted value).
The results of the PFTs are presented in Table 2.
Lung Biopsy Results
The most common histopathological diagnosis was GLILD
(seven cases), with a predominance of the LIP pattern
(five cases; Figure 5). Microscopic features of LIP were
dominated by abundant diffuse interstitial infiltrates
of lymphoid cells composed of CD3+ and CD20+
lymphocytes. In some patients, the inflammatory infiltration
formed clusters with single, small lymph nodules. In
addition to the intensive interstitial infiltration, a marked
peribronchial and perivascular chronic inflammation was
present (Figure 6).
Foci of COP and FB were found in addition to LIP features in
one of the patients (Figure 7).
Interstitial lymphocytic infiltrates were accompanied by
the presence of multiple non-necrotizing granulomas in
two children.
In the child diagnosed with NBS, the only histopathological
abnormality in the lung biopsy was non-necrotizing granulomas.
In two patients (No. 6 and 10), a mediastinal lymph node
biopsy was performed and revealed non-caseating granulomas.
Treatment Strategies
In eight children with PID-related ILD, the immunosuppressive
treatment was introduced (No. 1–8). In three patients (No.
3, 7, and 8) severe pulmonary symptoms were the only
reason for initiating the treatment. Patients 1, 4, 5, and
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FIGURE 1 | (A) Lung high-resolution computed tomography (HRCT): multiple, poorly defined nodules merging in larger areas of ground-glass opacities and
consolidations. (B) Lung HRCT: complete regression of pulmonary changes; residual irregular linear opacities are visible. (C) Chest X-ray: diffuse poorly defined
nodules creating larger areas of lung consolidations with adjacent areas of ground-glass opacities. Middle and lower zone predominance is clearly marked. (D) Chest
X-ray: complete resolution of pulmonary opacities with residual irregular linear thickenings.
FIGURE 2 | Lung high-resolution computed tomography: multiple
ground-glass and solid nodules scattered across the lungs, with perylimphatic
distribution. Larger clusters of nodules and tree-in-bud pattern are visible
peripherally.
6 (one symptomatic, three asymptomatic) were treated due
to autoimmune cytopenia and/or lymphoproliferation with
coexisting extensive lung involvement. Patient No. 2, who
didn’t present with respiratory symptoms, was qualified for
treatment because of decreased DLCO results, progression of
FIGURE 3 | Lung high-resolution computed tomography: multiple small
pulmonary nodules with perilymphatic distribution (clearly seen along pleural
fissures).
lung infiltrates in chest HRCT and features of fibrosis in the
lung biopsy.
Three patients, due to a lack of clinical symptoms and stable,
low-intensity changes in the lung HRCT, did not qualify for any
immunosuppressive therapy (No. 9, 10, and 11).
Systemic glucocorticoids (GCs) were introduced in all eight
children at the onset of treatment. Two children were initially
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treated with corticosteroid pulses. GCs were the only drugs used
in four patients (No. 2, 4, 6, and 7). In one of the patients
(No. 4), initially a recurrence of symptoms was observed during
GC dose reduction. It is worth noting that despite the treatment
discontinuation after the patient’s decision at the age of 18, he
remains clinically and radiologically stable. In patient No. 7, a
recurrence of ILD occurred after an asymptomatic period of
several months. Patient No. 6 (clinically asymptomatic) started
treatment with GCs due to autoimmune hemolytic anemia.
Hematological improvement after 3 months of GC therapy was
achieved, without resolution of radiological findings.
GC treatment resulted in rapid improvement of general
condition and resolution of respiratory failure in patient
No. 3. However, exercise intolerance, significant radiological
abnormalities, and abnormal PFT results persisted despite
the therapy.
Two boys were additionally treated with azathioprine
(No. 1 and 3), achieving a meaningful clinical improvement,
but due to serious side effects of the therapy (Table 3), the
treatment was discontinued. In patient No. 1, mycophenolate
mofetil was introduced, but the treatment was ineffective
(thrombocytopenia did not resolve) so the boy was eventually
FIGURE 4 | Contrast-enhanced lung computed tomography (soft tissue
window): marked enlargement of mediastinal and hilar lymph nodes with areas
of subpleural lung consolidations.
qualified for HSCT. The post-transplant period was complicated
by infections caused by HHV-6, Pneumocystis jiroveci and
Streptococcus viridans shortly after transplantation. After
HSCT a resolution of respiratory symptoms and regression of
pulmonary abnormalities in imaging studies were achieved.
Some months after the transplantation, due to the refractory
thrombocytopenia, splenectomy was performed with a
satisfactory effect. Despite the discontinuation of azathioprine,
patient No. 3 maintained the significant clinical and radiological
improvement obtained on the therapy (Figures 1B,D). In patient
No. 8, the resolution of ILD symptoms was achieved after adding
cyclosporin to GCs.
All of the patients remain alive. A clinical and radiological
improvement or stability of the lung disease is observed in all
the patients.
Significant side effects were observed during the
immunosuppressive treatment. Six children treated with
GCs presented with symptoms of Cushing syndrome. In patient
No. 3, compression fractures of the lumbar vertebrae occurred
due to post-steroid osteoporosis.
The azathioprine treatment was complicated by pancreatitis in
patient No. 1 and by liver damage with cholestasis in patient No.
3. In both patients, signs of drug-induced organ damage resolved
after discontinuation of the treatment. Transient cytopenia and
elevated transaminase levels were observed during the treatment
with rapamycin (second-line therapy, patient No. 5). In this case,
almost total resolution of radiological changes was observed.
All of the children were receiving IgRT during the study.
The treatment strategies are presented in Table 3.
DISCUSSION
Clinical presentations of PIDs are diverse, and PIDs are often
a diagnostic challenge. This is due in part to pulmonary
changes in patients with PIDs, as these changes may have
different etiologies and varied clinical as well as radiological
presentations, including ILD. Although our study showed a low
prevalence of PID-related ILD in children, it highlights various
clinical courses of ILDs, including life-threatening complications.
Importantly, the study demonstrated that ILD may precede
PID diagnosis and that the response to corticosteroids is
TABLE 2 | Results of pulmonary function tests.
Pulmonary function tests Patient 1 2 3 4* 5 6 7* 8 9 10 11
Spirometry FEV1, percentile 94 15.64 0.03 11.39 ND 75 22 ND 29.96 25.43 97.03
FVC; percentile 10 18.50 0.02 7.08 ND 50 13 ND 48.97 13.91 80.49
FEV1/FVC; percentile 38 36.29 84.84 46.88 ND 70 80 ND 20.11 60.37 94.58
Plethysmography RV; percentile ND 100 0.07 99.98 ND 97 ND ND 100 100 100
TLC; percentile ND 99.96 0.0 90.35 ND >99 ND ND 99.82 98.94 99.97
RV/TLC; percentile ND 99.91 0.78 99.62 ND 73 ND ND 99.94 99.82 99.17
Diffusing capacity for carbon monoxide DLCO; percentile ND 0 0 55.08 ND 41 ND ND 97.39 90.13 ND
*Lung function tests were performed in a stable phase of the disease, during treatment.
ND, No data.
DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.
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FIGURE 5 | Lung parenchyma with diffuse interstitial and peribronchiolar
lymphocytic infiltration. Microphotograph: hematoxylin and eosin stain.
usually prompt. However, the resolution of pulmonary changes
may be incomplete and a second-line treatment may be
necessary in some patients. It should be highlighted that in 3
patients, the initial symptoms suggested CVID. However, further
observation and the occurrence of other symptoms, including
those suggestive of ILD, led to an in-depth diagnostics and the
final diagnoses were established based on genetic testing. The
achieved diagnoses resulted in changing both, the diagnostic (e.g.,
NBS) and therapeutic (e.g., DGS and LRBA) management. We
would like to emphasize that this is the largest case series on
PID-related ILDs ever reported in a pediatric population. Thus,
we believe our findings may add to the existing literature on
the topic.
GLILD was originally described in patients with CVID (17).
Currently, there is a growing number of studies reporting this
disease in other PIDs, including DGS and LRBA deficiency
(24–26). Moreover, interstitial lymphocytic lung disease was
recognized in 4 NBS patients (11%) described by Deripapa et al.
(27). However, in the largest group of NBS patients, published
by Wolska-Kuśnierz et al., infections clearly dominated among
pulmonary complications (28).
The clinical picture of PID-related ILD in our study was very
diverse. It should be stressed that in two of the 11 children
(No. 3 and 7), ILD was the first presentation, documented
even before PID diagnosis. Similar sequences of symptoms and
diagnosis were recently reported in adults (29). Importantly,
in both children, the presenting symptoms were severe and
progressed to respiratory failure. The first child had four
episodes of ILD exacerbations with respiratory failure and
biopsy-proven LIP diagnosis 3 years before CVID diagnosis.
In the second child, pulmonary signs and symptoms, which
were initially interpreted as pneumonia, deteriorated rapidly to
respiratory failure (Figures 1A,C). The clinical picture, imaging
studies, and lung biopsy were consistent with GLILD, but the
definitive diagnosis of CVID was established only 7 months
later. Respiratory failure also occurred in the other child, but
FIGURE 6 | Diffuse intensive lymphocytic infiltration, both interstitial and
around blood vessels. Alveolar spaces are filled with numerous macrophages.
Microphotograph: hematoxylin and eosin stain.
FIGURE 7 | Diffuse interstitial inflammation with small focus of organizing
pneumonia (black arrow). The surrounding alveoli are filled with numerous
macrophages. Microphotograph: hematoxylin and eosin stain.
in contrast to the patients mentioned above, ILD symptoms
appeared 3 years after the diagnosis of NBS.
In contrast to the three patients with severe lung disease, the
majority of children with PID-related ILD were asymptomatic
or presented mild respiratory symptoms, but had extensive
pulmonary involvement in imaging studies. Thus, we strongly
agree with the British Lung Foundation/United Kingdom
Primary Immunodeficiency Network Consensus (BLF/UKPINC)
that patients with CVID should be screened for pulmonary
complications despite the absence of symptoms. HRCT,
lung function tests, and other diagnostic procedures are
recommended as a part of the diagnostic workup (30). Regular
clinical monitoring for lung involvement should also apply to
patients with other PIDs (31).
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TABLE 3 | Treatment strategies.
Patient (lung
biopsy)
Treatment line Treatment effect Treatment complications Comments
1(GLILD/LIP) First Line: DEX 1.0 mg/kg 10 days,
PRED, initial dose: 1.0 mg/kg,
maintenance dose: 0.2 mg/kg
Clinical and radiological
improvement, but persistence of
residual lesions in lung HRCT
Cushing syndrome Introduction of second-line
treatment
Second Line (1): AZA 2mg/kg Clinical stabilization Pancreatitis Due to pancreatitis, AZA was
changed to MMF
Second Line (2): MMF 500 mg/day Clinical and radiological
progression




low dose of steroids and MMF
Patient qualified for HSCT,
infectious complications after HSCT
(HHV-6, Pneumocystis jiroveci, Str.
viridans), splenectomy due to
refractory thrombocytopenia and
finally clinical and radiological
improvement
2 (GLILD/LIP) PRED initial dose: 0.75 mg/kg,
maintenance dose: 0.33 mg/kg for
6 months
Radiological improvement – Patient had no clinical respiratory
symptoms
3 (GLILD) First Line: MPRED i.v. pulses 3 days
(30 mg/kg), PRED initial dose: 2.0
mg/kg, maintenance dose: 0.4
mg/kg
Resolution of respiratory failure,
incomplete clinical (exercise
intolerance) and radiological (partial




fractures of lumbar vertebrae
Clinical and radiological
deterioration observed while
reducing the steroid dose;
therefore, AZA was introduced
Second Line: AZA 2.0–3.5 mg/kg Significant clinical and radiological
improvement
Hepatitis with liver injury and
cholestasis
AZA dose was modified depending
on the 6-thioguanine levels; due to
adverse effects, treatment was
discontinued
4 (GLILD/LIP) PRED initial dose: 2.0 mg/kg,
maintenance dose: 0.6 mg/kg
Resolution of clinical symptoms,
partial radiological improvement
Cushing syndrome Recurrence of radiological changes
while trying to discontinue the drug
5 (GLILD/LIP) First Line: PRED initial dose: 2.0
mg/kg, maintenance treatment:
MPRED 0.1 mg/kg in tapered doses




Second Line (1): MMF 400 mg/day Almost total resolution of
radiological changes
MMF was introduced almost
simultaneously with PRED




Due to thrombocytopenia, MMF
was replaced with RAP
6 (GLILD) PRED initial dose: 0.7 mg/kg,
maintenance dose: 0.5 mg/kg
Without radiological improvement Cushing syndrome, depression The patient reports periodically a
subjective feeling of dyspnea
7 (GLILD/LIP) PRED initial dose: 2.0 mg/kg,
maintenance dose 0.2 mg/kg
Significant clinical and radiological
improvement
Cushing syndrome
8 (G) First Line: PRED Initial dose: 1.0





Second Line: CsA 2.5–3.0 mg/kg Clinical stabilization
AZA, azathioprine; CsA, cyclosporine A; DEX, dexamethasone; G, granulomas; GLILD, granulomatous-lymphocytic interstitial lung disease; HSCT, hematopoietic stem cell
transplantation; HRCT, high-resolution chest tomography; LIP, lymphocytic interstitial pneumonia; MMF, mycophenolate mofetil; MPRED, Methylprednisolone; PRED, prednisone;
RAP, rapamycin.
In addition to respiratory symptoms, patients with PIDs
present with a wide spectrum of symptoms involving other
organs. In a significant number of patients, autoimmune
cytopenias, especially autoimmune thrombocytopenia, are
observed as the first manifestation of the disease (32). This
was the case of two our patients with autoimmune cytopenia,
in whom autoimmune cytopenia was the first presenting
symptom. Quinti et al. described autoimmune cytopenia as the
only complication in 2.3% of CVID patients and autoimmune
phenomena as the most common complication [17%; (33)].
Lymphadenopathy, hepatomegaly, and splenomegaly were the
most common presentations in our study group. The other
non-infectious manifestations included chronic diarrhea, allergic
diseases, lymphoid hyperplasia, and failure to thrive.
GLILD can be also found as a serious complication of PIDs
in adults. As in children, the clinical course of PID-related ILD
in adults can be asymptomatic. Symptomatic patients usually
present with dyspnea, tachypnea, cough, exercise intolerance of
various severity, and crepitations. Similar to children, hypoxemic
respiratory failure may occur in the most severe cases (17, 29, 34).
According to the BLF/UKPINC, the most typical radiologic
findings in GLILD are solid or semisolid nodules, ground-glass
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opacities, and enlarged thoracic lymph nodes (30). These data
are consistent with our observations. Nodules of different sizes
and densities were found in all children, with perilymphatic
distribution (along pleura, fissures, interlobular septa, and
bronchovascular bundles) predominating in eight out of 11
patients. A similar distribution of nodules was previously
observed in patients with CVID-related ILD (35–38). However,
other radiographic patterns were also reported, including
random distribution (35–37, 39, 40) and mixed distribution with
randomly scattered small nodules (<5mm) and peribronchial
localization of larger nodules (39).
Ground-glass opacities were identified in four patients with
PID-related ILD. In GLILD, patchy areas of ground-glass
opacities are usually located peripherally and in peribronchial
and subpleural regions. These changes may reflect organizing
pneumonia areas (10, 35, 39, 41, 42). “Halo sign” was found in
two patients in our study group. Bouvry et al. reported that this
sign was a common feature of GLILD and was associated with
the presence of granulomas, which may be surrounded by foci of
organizing pneumonia (37).
In two of the children in this study, CT revealed a tree-in-
bud pattern. This pattern may reflect a spectrum of endo- and
peribronchiolar disorders, including mucoid impaction. Tree-
in-bud sign was reported by Bang et al. in CVID patients
with pulmonary infections (43). This sign may also reflect
non-infectious peribronchial or bronchiolar inflammation and
was found in patients with follicular bronchiolitis (44) or, less
commonly, in organizing pneumonia (44, 45).
In our patients, lung HRCT did not reveal reticular
abnormalities, which appear to be common features of GLILD in
adults (17, 39–41, 46). As reticular opacities seem to be features of
more advanced stages of ILD (47), we propose that the presence
of a reticular pattern in adults is associated with more prolonged
lung involvement resulting in irreversible fibrotic changes in the
lung architecture.
The data on pulmonary function in patients with PID-related
ILDs mainly come from adult studies. Restrictive or mixed
obstructive and restrictive patterns, as well as decreased DLCO,
were the most frequently observed abnormalities. However, it
must be underlined that the results of PFT can be completely
normal in the majority of patients (14, 35, 43). Similar
observations were made in the very few studies on children.
A restrictive pattern was reported by Tillman et al. in a 13-
year-old girl with GLILD and by van de Ven et al. in eight
children with CVID and CVID-like disease (48, 49). In our study,
restrictive pulmonary dysfunction was demonstrated in one
child (patient No. 3). Interestingly, an increased RV/TLC ratio
indicating air trapping in the absence of FEV1/FVC reduction
was the most common finding in our study. According to some
authors, an increased RV/TLC ratio may be a more sensitive
indicator of airflow obstruction than the FEV1/FVC ratio (50,
51). This parameter is thought to reflect distal airway narrowing
or closure resulting from inflammation (50, 51). As nodular
peribronchiolar lymphocytic inflammation is common in CVID
patients with GLILD (52), we can hypothesize that our findings
reflect small airway obstruction caused by an increased number
of lymphocytes in this region. Decreased DLCO, which is an
early indicator of ILD (35, 36), was noted in two of our patients
(No. 2 and 3).
In the light of data demonstrating that GLILD is associated
with significantly increased mortality in patients with CVID,
identifying an effective treatment is a critical issue (16). Although
no standard treatment has been established, the consensus
statement of the BLF/UKPINC (30) recommends optimizing
IgRT as an initial step in the treatment of CVID. However, despite
adequate IgRT, complications like CVID-related ILD may occur
in some patients, making additional therapy necessary.
According to the aforementioned consensus statement,
systemic corticosteroids should be applied as the first-line
therapy in symptomatic patients. In our group, GCs were
administered to all eight patients who required an intervention
in addition to IgRT. In four patients decision about treatment
was made due to the coexistence of autoimmune cytopenia or
lymphoproliferation and extensive lung involvement in imaging
studies. In patient No. 2 the treatment with GCs was started
owing to significant progression in imaging studies, decreasing
DLCO, as well histopathological features of irreversible lung
scarring. The use of GCs as monotherapy led to rapid
improvement in almost all the treated individuals. Their
effectiveness was particularly evident in patients with the most
severe cases of ILD (No. 3, 7, and 8), whose respiratory failure
resolved in response to the treatment. However, in the four
patients who did not fully respond to the first-line therapy,
developed significant side effects, or presented with disease
exacerbation during steroid tapering, second-line treatment
was applied. The second-line treatment drugs that were
effective in our group were mycophenolate mofetil, azathioprine,
cyclosporin A and rapamycin. These agents improved the clinical
course of GLILD in three of our patients. However, it should
be stressed that immunosuppressive treatment was associated
with several significant side effects. Among the most relevant
were: leucopenia after MMF treatment; pancreatitis, liver injury
with hypertransaminasemia and cholestasis after azathioprine
therapy; leucopenia and hypertransaminasemia after rapamycin
treatment and advanced osteoporosis with compression fractures
of lumbar vertebrae after GCs therapy (Table 3). In our study,
we used either GCs alone (four patients) or a combination of
immune-modulating agents (four patients). Since the second-line
drugs rapamycin and azathioprine are directed toward T cells,
they are effective in GLILD patients, whose lung biopsies are
known to contain infiltrates with T cells. We found that this type
of therapy brought about subjective and objective resolution of
ILD in PAD patients. As reported by other authors, similar effects
may be obtained with the CTLA-4 fusion protein abatacept. The
effectiveness of this treatment has been documented, particularly
in patients with LRBA deficiency (53–55). Our patient with
LRBA deficiency was treated with GCs as a first-line therapy, and
mycophenolate mofetil and rapamycin as a second-line therapy,
but did not receive abatacept treatment.
As lung infiltrates also consist of CD20+ B cells,
clinical improvement in GLILD may also be achieved after
administration of the anti-CD20 antibody rituximab as
monotherapy (56) or in combination with azathioprine, as
reported by some groups (48, 57).
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HSCT is not considered to be a standard therapeutic option
in patients with GLILD (5). However, HSCT was reported
to be applied to some patients with malignancies, refractory
autoimmune cytopenias, ILD/GLILD, and/or autoimmune
enteropathy, among others in patients with LRBA deficiency
(58). As reported by Tesch et al., HSCT in these patients was
associated with an increased risk of death in the course of early
post-transplant complications, but HSCT survivors achieved
remission of disease symptoms (including ILD), in contrast to
patients who had not undergone transplantation (55). The overall
survival rate of patients undergoing HSCT was 70.8%, and the
vast majority (70.6%) didn’t require further immunosuppressive
treatment (55).
Since only one of our patients was treated with HSCT due
to refractory autoimmune cytopenia, we did not feel entitled
to enclosing a more extensive discussion or drawing any
binding conclusions.
Strength and Limitations of the Study
To our knowledge, this is the largest study on children with PID-
related ILD (mostly CVID patients) published so far, presenting
detailed description of clinical, radiological, and histological
signs of ILD/GLILD. Additionally, the analysis of the first- and
second-line treatments is presented.
However, this study also has some limitations. First of all, it
is a retrospective analysis. As a consequence of the study design,
there are further drawbacks, including genetic diagnosis in only
a few patients and non-uniform assessment and treatment.
It is important to point out that two of the three children with
themost advanced lung disease were not able to perform PFT due
to young age or intellectual disability. Finally, the type of ILD was
not confirmed by surgical lung biopsy in three of the children.
We believe that our study clearly points out the need for
developing a uniform and commonly accepted diagnostic and
therapeutic algorithm for patients with PID and coexisting ILD.
Special attention should be paid to early radiological detection
of lung involvement with the use of HRCT. This is supported by
our finding that some asymptomatic patients with PID-related
ILDmay present with advanced structural lung alterations. It also
seems necessary to propose amore uniform therapeutic approach
and to gather more long-term observations on the relationship
between treatment regimen and disease outcomes.
CONCLUSIONS
Our analysis showed that the clinical presentation of PID-related
ILD can be diverse, ranging from asymptomatic presentation
to life-threatening disease. It should be emphasized that ILD
symptoms may precede the diagnosis of PID and that aggressive
treatment, especially in patients with a rapid clinical course,
provides fast but sometimes incomplete improvement. Although
corticosteroids seem to be effective in the treatment of PID-
related ILD, even in severe cases, the optimal treatment of PID-
related ILD patients is hindered by the lack of clinically proven
treatment regimens for these diseases. Hence, there is a need
for a well-designed, multicenter study that includes an adequate
number of patients, including pediatric population, to determine
the most effective treatment strategies and the optimal duration
of the therapy.
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